Ensign Peak Advisors
LBPH

Ensign Peak Advisors’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Ensign Peak Advisors’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-301,161
Closed -$1.82M – 1776
2023
Q4 		$1.82M Buy
+301,161
New +$1.5M ﹤0.01% 958

Other funds holding LBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ensign Peak Advisors's LBPH Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q1 2024, closing a stake of 301,161 shares — an estimated $1.82M sold.

Ensign Peak Advisors first reported a position in LBPH in Q4 2023 and held it in 1 quarter. The position peaked at $1.82M in Q4 2023. 105 funds tracked by Wall St. Rank hold LBPH as of Q1 2024.

  • Ensign Peak Advisors reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 301,161 Longboard Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $1.82M.
  • Ensign Peak Advisors first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Ensign Peak Advisors's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $1.82M in Q4 2023.
  • 105 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.